# Neil M.H. Graham

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/neil-m-h-graham/

## Facts

| Field | Value |
| --- | --- |
| Citations | 34,605 |
| Field | Asthma and respiratory diseases |
| h-index | 81 |
| i10-index | 191 |
| Last Known Institution | UK Dementia Research Institute |
| OpenAlex ID | https://openalex.org/A5077395512 |
| ORCID iD | https://orcid.org/0000-0002-1236-2311 |
| Works | 320 |

## Researcher papers

Showing 12 of 19.

- [Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis](https://scholariq.org/papers/two-phase-3-trials-of-dupilumab-versus-placebo-in-atopic-dermatitis/)
- [Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma](https://scholariq.org/papers/dupilumab-efficacy-and-safety-in-moderate-to-severe-uncontrolled-asthma/)
- [Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis](https://scholariq.org/papers/dupilumab-treatment-in-adults-with-moderate-to-severe-atopic-dermatitis/)
- [Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial](https://scholariq.org/papers/long-term-management-of-moderate-to-severe-atopic-dermatitis-with-dupilumab-and/)
- [Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma](https://scholariq.org/papers/efficacy-and-safety-of-dupilumab-in-glucocorticoid-dependent-severe-asthma/)
- [Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis](https://scholariq.org/papers/dupilumab-progressively-improves-systemic-and-cutaneous-abnormalities-in/)
- [Dementia in AIDS patients](https://scholariq.org/papers/dementia-in-aids-patients/)
- [Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial](https://scholariq.org/papers/efficacy-and-safety-of-dupilumab-in-adults-with-moderate-to-severe-atopic/)
- [Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis](https://scholariq.org/papers/efficacy-and-safety-of-dupilumab-in-adolescents-with-uncontrolled-moderate-to/)
- [Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical t](https://scholariq.org/papers/dupilumab-with-concomitant-topical-corticosteroid-treatment-in-adults-with/)
- [Conjunctivitis in dupilumab clinical trials](https://scholariq.org/papers/conjunctivitis-in-dupilumab-clinical-trials/)
- [Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial](https://scholariq.org/papers/efficacy-and-safety-of-dupilumab-with-concomitant-topical-corticosteroids-in/)

## Researcher topics

- [Asthma and respiratory diseases](https://scholariq.org/topics/asthma-and-respiratory-diseases/)
- [Dermatology and Skin Diseases](https://scholariq.org/topics/dermatology-and-skin-diseases/)
- [Allergic Rhinitis and Sensitization](https://scholariq.org/topics/allergic-rhinitis-and-sensitization/)
- [HIV Research and Treatment](https://scholariq.org/topics/hiv-research-and-treatment/)
- [IL-33, ST2, and ILC Pathways](https://scholariq.org/topics/il-33-st2-and-ilc-pathways/)

## Researcher university

- [UK Dementia Research Institute](https://scholariq.org/institutions/uk-dementia-research-institute/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.